Tag Archives: EGRX

A Director at Eagle Pharmaceuticals is Exercising Options

Yesterday it was reported that a Director at Eagle Pharmaceuticals (EGRX – Research Report), Steven Ratoff, exercised options to buy 2,340 EGRX shares at $8.78 a share, for a total transaction value of $20.55K. The options were close to expired

Eagle Pharmaceuticals (EGRX) Gets a Buy Rating from RBC Capital

RBC Capital analyst Randall Stanicky maintained a Buy rating on Eagle Pharmaceuticals (EGRX – Research Report) today and set a price target of $59.00. The company’s shares closed last Monday at $40.94. According to TipRanks.com, Stanicky is currently ranked with

RBC Capital Sticks to Its Buy Rating for Eagle Pharmaceuticals Inc (EGRX)

In a report issued on August 8, Randall Stanicky from RBC Capital maintained a Buy rating on Eagle Pharmaceuticals Inc (EGRX – Research Report), with a price target of $66. The company’s shares closed on Friday at $56.99. According to

Cantor Fitzgerald Sticks to Their Hold Rating for Eagle Pharmaceuticals Inc (EGRX)

In a report released today, Brandon Folkes from Cantor Fitzgerald reiterated a Hold rating on Eagle Pharmaceuticals Inc (EGRX – Research Report), with a price target of $58. The company’s shares opened today at $57.71. Folkes commented: “. Post 1Q19,

Eagle Pharmaceuticals Inc (EGRX) Gets a Hold Rating from Mizuho Securities

In a report released yesterday, Irina Rivkind Koffler from Mizuho Securities maintained a Hold rating on Eagle Pharmaceuticals Inc (EGRX – Research Report), with a price target of $50. The company’s shares closed yesterday at $52.04. According to TipRanks.com, Koffler

Eagle Pharmaceuticals Inc (EGRX) Gets a Hold Rating from Cantor Fitzgerald

In a report released today, Brandon Folkes from Cantor Fitzgerald maintained a Hold rating on Eagle Pharmaceuticals Inc (EGRX – Research Report), with a price target of $58. The company’s shares opened today at $47.51. Folkes commented: “Eagle has carved